2006.63: The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy

2006.63: R. B. Van Dyke, B. T. Korber, E. Popek, C. Macken, S. M. Widmayer, A. Bardeguez, I. C. Hanson, A. Wiznia, K. Luzuriaga, R. R. Viscarello, S. Wolinsky and the Ariel Core Investigators (1999) The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. Journal of Infectious Diseases, 179 (2). pp. 319-328. ISSN 0022-1899

Full text available as:

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 169 Kb

Official URL: http://www.journals.uchicago.edu/JID/journal/issues/v179n2/980128/980128.html

Abstract

In a prospective cohort study, clinical and biologic factors that contribute to maternal-child transmission of human immunodeficiency virus type 1 (HIV-1) were studied. HIV-infected pregnant women and their infants were evaluated prospectively according to a standardized protocol. Of 204 evaluable women, 81% received zidovudine during their pregnancy. The infection rate among the 209 evaluable infants was 9.1%. By univariate analysis, histologic chorioamnionitis, prolonged rupture of membranes, and a history of genital warts were significantly associated with transmission. Additional factors associated with transmission that approached significance included a higher maternal virus load at delivery and the presence of cocaine in the urine. In a logistic regression model, histologic chorioamnionitis was the only independent predictor of transmission. Despite a significantly higher transmission rate at one site, no unique viral genotype was found at any site. Thus, chorioamnionitis was found to be the major risk factor for transmission among women receiving zidovudine.

Download Statistics: last 4 weeks
Repository Staff Only: edit this item